New focus to combat rising liver disease
The Abbott RealTime HCV Genotype II can distinguish between genotypes 1, 1a, 1b, 2, 3, 4, and 5, using an infected person’s blood sample. Knowing the virus’s genotype can help doctors determine the best treatment, the agency said Thursday in a news release.
Hepatitis C is the most common chronic blood-borne infection in the United States, and the leading cause of liver transplant, the FDA said, citing the U.S. Centers for Disease Control and Prevention (CDC). Some 3.2 million people are infected with the virus, and about 15,000 people die from the infection every year.
Untreated, hepatitis C can lead to liver cancer and liver failure, the agency warned. The virus is transmitted via blood and other bodily fluids, and intravenous drug users are at greatest risk of acquiring the infection.
The new test is approved for people who are known to have the infection. It is not meant as a way to diagnose hepatitis C, or as a way to screen for the virus’s presence in the blood, the FDA said.
The test has not been evaluated in children or in people with compromised immune systems, the agency said. It is manufactured by Abbott Molecular, Inc., based in Des Plaines, Ill.
University of Adelaide researchers are investigating how the liver responds to hepatitis C virus (HCV) and why some people can control the virus while others can’t. The aim is to find better therapies to combat hepatitis C and associated liver disease.
Speaking ahead of World Hepatitis Day (Sunday 28 July), Head of the Hepatitis C Virus Research Laboratory Associate Professor Michael Beard says the burden of disease from the hepatitis C virus is rapidly escalating.
“A large number of people were infected with HCV in the 1970s and 1980s before isolation of the virus in 1989, and we’re now seeing those people emerging with liver disease,” says Associate Professor Beard. “Unfortunately, liver cancer as a result of HCV infection is on the rise and is expected to double by 2020.”
HCV is blood-borne and contracted primarily through injecting drug use and, before bloodbank screening for HCV started in 1990, through blood-transfusion. Unchecked hepatitis C can lead to chronic disease and liver cancer and there are currently more than 220,000 Australians living with chronic hepatitis C.
A unique feature of infection with HCV is that about 75% of individuals develop a chronic infection while 25% spontaneously clear the virus.
“We hope to understand why some people can combat the virus without drugs and why others can’t,” says Associate Professor Beard. “We’ll be looking at how the liver cells respond to HCV infection to see how genes are being regulated and how this, in turn, impacts virus replication and liver disease.”
“If we can better understand this process, we will be able to use this information to help develop a vaccine or improved antiviral drugs.” Vaccines exist for hepatitis A and B, but not for hepatitis C.
The Adelaide researchers will be using live imaging of the virus in cultured liver cells to investigate the interactions between the liver cell and the virus in real time.
“Up until now, we’ve only been able to look at virus infection in a particular snap-shot in time. Now we can look at the dynamics between the cell and the virus, within a living cell,” Associate Professor Beard says.
“We’re also investigating how some of the emerging new classes of antiviral drugs work and what their mode of action is. This will help develop the next generation of antiviral drugs against HCV.”
The research is funded by the National Health and Medical Research Council (NHMRC) under a $5.5 million program grant with University of Sydney and University of NSW, starting in 2014.
Associate Professor Beard is also convenor of the 20th International Symposium on Hepatitis C Virus and Related Viruses which meets in Melbourne in October and will discuss the latest knowledge in hepatitis therapies and disease.
More information: The CDC has more about hepatitis C.
